Data Sheet 3_A malignancy risk prediction model for Bethesda category III thyroid nodules based on serological indicators, C-TIRADS, and BRAF V600E testing.csv

Objective<p>To investigate the diagnostic value of a multimodal prediction model integrating thyroglobulin antibody (TgAb), thyroid peroxidase antibody (TPOAb), the Chinese Thyroid Imaging Reporting and Data System (C-TIRADS), and BRAF V600E mutation status, for evaluating the malignancy risk in Bethesda Category III thyroid nodules.</p>Methods<p>We retrospectively enrolled 93 patients whose thyroid nodules were diagnosed as Bethesda Category III via fine-needle aspiration and subsequently underwent surgical treatment at Northern Jiangsu People’s Hospital between July 2020 and June 2025.

Preoperative TgAb levels, TPOAb levels, C-TIRADS classification, and BRAF V600E mutation status data were collected. A malignancy risk prediction model was constructed using Firth’s penalized likelihood logistic regression. The diagnostic performance of individual indicators and the combined model was evaluated using receiver operating characteristic (ROC) curves.